Skip to the page

Data / Drug companies / Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc.: 13 products in the FDA NDC directory, labeler code 59417

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Takeda Pharmaceuticals America, Inc. (labeler code 59417) lists 13 products in the FDA National Drug Code Directory, covering 1 finished drug by generic name. By type: 13 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 28, 2017.

The request: Watch Takeda Pharmaceuticals America, Inc. (FDA labeler code 59417): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
59417
Products in commercial distribution
13
Packages
13
Finished drugs by generic name
1
Prescription products
13
Over the counter products
0
Controlled substance products
Schedule II 13
Flagged as original packager
13 of 13 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
February 23, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)13100%

Products by type

TypeProductsShare
Prescription drugs13100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Lisdexamfetamine dimesylate1316

Dosage forms

Dosage formProductsShare
Capsule753.8%
Tablet, chewable646.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Vyvanse59417-120Tablet, chewableNew drug applications (NDA)January 28, 2017
Vyvanse59417-119Tablet, chewableNew drug applications (NDA)January 28, 2017
Vyvanse59417-118Tablet, chewableNew drug applications (NDA)January 28, 2017
Vyvanse59417-117Tablet, chewableNew drug applications (NDA)January 28, 2017
Vyvanse59417-116Tablet, chewableNew drug applications (NDA)January 28, 2017
Vyvanse59417-115Tablet, chewableNew drug applications (NDA)January 28, 2017
Vyvanse59417-101CapsuleNew drug applications (NDA)August 30, 2014
Vyvanse59417-106CapsuleNew drug applications (NDA)December 10, 2007
Vyvanse59417-104CapsuleNew drug applications (NDA)December 10, 2007
Vyvanse59417-102CapsuleNew drug applications (NDA)December 10, 2007
Vyvanse59417-107CapsuleNew drug applications (NDA)February 23, 2007
Vyvanse59417-105CapsuleNew drug applications (NDA)February 23, 2007
Vyvanse59417-103CapsuleNew drug applications (NDA)February 23, 2007

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.